Nana Liu^1,2, Jinjin Zhang², Wanli Liu², Xiangbo Chen^2,*, Baoli Li^1,*

Canadian Journal of Urology, Vol.33, No.4, pp. 989-997, 2026, DOI:10.32604/cju.2026.084512 - 21 August 2026

Abstract Background: Transurethral resection of the prostate (TURP) remains the standard surgical treatment for benign prostatic hyperplasia (BPH), whereas laser-based procedures have increasingly been adopted as alternatives because of their potential advantages in hemostasis and postoperative recovery. This study compared coagulation depth, perioperative outcomes, postoperative complications, and short-term functional outcomes between 450-nm blue laser vaporization of the prostate (BVP) and TURP. Methods: This retrospective single-center study included 260 patients with BPH who underwent either TURP (n = 110) or BVP (n = 150). Coagulation depth was compared between the two procedures using an ex vivo porcine kidney… More >

Jonathan J. Song¹, I-Chun (Jinn) Thomas², Amber Herbert³, Calyani Ganesan^2,3,4, Alan C. Pao^2,3,4, Timothy Chang^2,3, Ryan R. Sun³, John T Leppert^2,3,4, Simon L Conti^3,*

Canadian Journal of Urology, Vol.33, No.4, pp. 903-912, 2026, DOI:10.32604/cju.2026.074683 - 21 August 2026

Abstract Background: The prevalence of urinary stone disease (USD) is increasing among older patients. Data examining the association between patient age and clinical outcomes following surgical treatment for USD are limited. Our objective was to assess the safety profiles of ureteroscopy (URS), extracorporeal shock wave lithotripsy (ESWL), and percutaneous nephrolithotomy (PCNL) for USD by age in an older patient population. Methods: We retrospectively identified all patients who underwent URS, ESWL, and PCNL for USD from 2010 to 2019 in the Veterans Health Administration. We fit multivariable logistic regression models to determine the association between age and… More >

Volkan Sabur^1,*, Abdullah Gölbaşı²

Canadian Journal of Urology, Vol.33, No.4, pp. 841-849, 2026, DOI:10.32604/cju.2026.074330 - 21 August 2026

Abstract Background: Recurrent prostate surgery may pose additional challenges for achieving an efficient and anatomically precise enucleation. This research investigates how prior transurethral resection of prostate (TURP) affects the perioperative course, functional outcomes, and technical difficulty of Holmium Laser Enucleation of the Prostate (HoLEP) when performed as a primary procedure versus as a salvage treatment. Methods: In this retrospective study, 174 patients who underwent HoLEP between August 2023 and April 2025 were analyzed. Group 1 included 137 patients undergoing primary HoLEP, and group 2 included 37 patients undergoing HoLEP for TURP recurrence. Outcomes assessed included enucleation… More >

Iseult M. Browne^1,2, Susanna Slater¹, Myrto Kastrisiou¹, Mae Alghawas¹, Edward Phillips¹, Mark Beresford³, Stephen R. D. Johnston¹, Zoe Kemp¹, Emma Kipps¹, Marina Parton¹, Nicholas C. Turner^1,2, Alicia F. C. Okines^1,2,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.085356 - 13 August 2026

Abstract Background: Adenoid cystic carcinoma (ACC) of the breast is a rare triple-negative malignancy with an indolent clinical course distinct from conventional triple-negative breast cancer (TNBC). Optimal management remains undefined due to limited prospective data. This study aimed to characterise the clinicopathological features, treatment patterns, and long-term outcomes of breast ACC at a high-volume specialist centre, contributing real-world evidence to inform management in the absence of prospective trial data. Methods: A single-institution retrospective cohort study was conducted of 24 patients with histopathologically confirmed breast ACC treated at The Royal Marsden NHS Foundation Trust between 2000 and… More >

Shih-Wei Chiang^1,2, Ming-Cheng Chen^2,3, Chang-Lin Lin², Yi-Lin Huang², Feng-Fan Chiang^2,4,*, Shun-Fa Yang^1,5,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.085229 - 13 August 2026

Abstract Background: Anti-EGFR therapy is widely used as first-line treatment for RAS wild-type metastatic colorectal cancer (mCRC), particularly in patients with left-sided tumors. In liver-limited disease, maximizing tumor shrinkage may facilitate conversion to resectability; however, comparative real-world evidence among panitumumab, cetuximab, and bevacizumab remains limited. This study aimed to compare the clinical outcomes of these biologic agents in patients with RAS wild-type mCRC. Methods: We retrospectively analyzed 241 patients with RAS wild-type mCRC treated with first-line chemotherapy plus panitumumab (n = 76), cetuximab (n = 80), or bevacizumab (n = 85) between 2016 and 2024. Outcomes included depth of response… More >

Krittiya Korphaisarn^1,#,*, Kosin Wirasorn^2,#, Suebpong Tanasanvimon³, Kijjakom Thanasombunsukh⁴, Kunlatida Maneenil⁵, Jirawat Thanestada⁶, Nattaya Teeyapun³, Jarin Chindaprasirt², Chirawadee Sathitruangsak⁷, Teerada Siripoon⁸, Phannin Tiraswasdichai⁹, Chanchai Charonpongsuntorn¹⁰, Passakorn Wanchaijiraboon¹¹, Wannisa Laosuangkoon¹², Patrapim Sunpaweravong⁷, Ekapop Sirachainan⁸, Charuwan Akewanlop¹

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.083206 - 13 August 2026

Abstract Introduction: Durvalumab plus tremelimumab (Durva/Treme) improved survival in the HIMALAYA trial for unresectable hepatocellular carcinoma (HCC), but real-world evidence remains limited. This study aimed to evaluate clinical outcomes of Durva/Treme in routine practice. Methods: This retrospective multicenter study included patients with unresectable or advanced HCC who received Durva/Treme through the Expanded Access Program in Thailand between August 2023 and November 2025. Treatment outcomes and adverse events (AEs) were analyzed and descriptively compared with the HIMALAYA trial. Results: Fifty patients were included; median age was 62 years and 80% were male. Etiologies included hepatitis B (44%), hepatitis C… More >

Xiaoxia Wang^1,2,#, Shuo Wang^1,2,#, Chendi Liang^1,2,#, Huili Wu^1,2, Songtao Liu^1,2, Jinhuan Wang^1,2, Jun Lu^1,2,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.082815 - 13 August 2026

Abstract Background: Invariant natural killer T (iNKT) cells show promise as immunotherapeutic agents for solid tumors, and our prior study demonstrated that combining iNKT-cell therapy with transarterial chemoembolization (TACE) achieved a 58.3% objective response rate (ORR) in hepatocellular carcinoma (HCC). This study further examines iNKT-mediated immune modulation of post-TACE survival dynamics and associated prognostic biomarkers. Methods: Clinical data and peripheral blood samples were obtained from 77 HCC patients in Beijing you’an Hospital between 2018–2023, including 38 receiving TACE alone and 39 receiving combined iNKT-cell/TACE therapy. Serial measurements included: Hematological parameters; Liver function tests [alanine aminotransferase (ALT), aspartate… More >

Carlo Signorelli^1,*, Michele Basso², Annunziato Anghelone², Maria Alessandra Calegari², Alessandro Passardi³, Chiara Gallio³, Alessandro Bittoni³, Jessica Lucchetti⁴, Lorenzo Angotti⁴, Emanuela Di Giacomo⁴, Ina Valeria Zurlo⁵, Cristina Morelli⁶, Emanuela Dell’Aquila⁷, Adele Artemi⁷, Donatello Gemma⁸, Domenico Cristiano Corsi⁹, Alessandra Emiliani⁹, Marta Ribelli⁹, Federica Mazzuca¹⁰, Giulia Arrivi¹⁰, Federica Zoratto¹¹, Maria Grazia Morandi¹², Fiorenza Santamaria^13,14, Manuela Dettori¹⁵, Antonella Cosimati¹⁶, Rosa Saltarelli¹⁷, Alessandro Minelli¹⁸, Emanuela Lucci-Cordisco¹⁹, Mario Giovanni Chilelli¹

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.080964 - 13 August 2026

Abstract Background: Trifluridine/tipiracil (T) is a standard treatment for refractory metastatic colorectal cancer (mCRC). In randomized trials, treatment-emergent neutropenia has been associated with improved outcomes, suggesting a potential link with drug activity. However, evidence from routine clinical practice remains limited. This sub-analysis of the multicenter ReTrITA study evaluated the association between severe neutropenia and clinical outcomes in a real-world setting. Methods: Patients with refractory mCRC treated with T within the ReTrITA cohort were included. Patients were stratified according to the occurrence of grade 3–4 neutropenia. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan–Meier… More >

Anusha Konduri^1,*, Toni Duganiero², Lauren Smyth², Shahnawaz Amdani³, Angela Lorts², Sabrina Law⁴, Jacqueline Lamour⁵, Deipanjan Nandi⁶, Aryaz Sheybani⁷, Sarah Wilkens⁸, Thomas Young⁹, Mark Bleiweis¹⁰, Jennifer Conway¹¹

Structural and Congenital Heart Disease, Vol.21, No.3, 2026, DOI:10.32604/schd.2026.082288 - 31 July 2026

Abstract Pediatric heart failure is associated with substantial morbidity, mortality, and health care utilization across diverse diagnoses and care settings. Despite major advances in surgical and medical care, evidence-based management of heart failure in the pediatric population, especially with congenital heart disease (CHD), remains limited due to a small patient population, marked anatomic and physiologic heterogeneity, and barriers to conducting traditional randomized clinical trials. Clinical registries have provided important insights into pediatric heart failure, and the increasing complexity of these populations has underscored the value of learning health system approaches to data generation and improvement. The… More >

Budi Rahmat¹, Dicky Fakhri¹, Rama Vinnu Isyawan¹, Ghitha Zahra Haifa^1,2,*

Structural and Congenital Heart Disease, Vol.21, No.3, 2026, DOI:10.32604/schd.2026.077573 - 31 July 2026

Abstract Background: Univentricular heart defects with unrestricted pulmonary blood flow are commonly managed using pulmonary artery banding (PAB) followed by bidirectional cavopulmonary shunt (BCPS) as part of staged palliation, but the optimal interval between these procedures remains uncertain. Methods: This retrospective cohort study evaluated the association between the PAB–BCPS interval and postoperative outcomes after BCPS in patients treated at the National Cardiovascular Center Harapan Kita, Indonesia, from January 2015 to January 2024. Patients with univentricular heart defects and unrestricted pulmonary blood flow who underwent BCPS after prior PAB were included, whereas those undergoing BCPS with major concomitant… More >